<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081236</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 09-2-125</org_study_id>
    <nct_id>NCT01081236</nct_id>
  </id_info>
  <brief_title>Intestinal Barrier Function and Liver Cirrhosis</brief_title>
  <official_title>The Role of the Intestinal Barrier Function in Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with liver cirrhosis have an increased risk to develop life-threatening
      complications such as spontaneous bacterial peritonitis (SBP). Impairment in the intestinal
      barrier, changes in numbers and composition of the intestinal microbiota and alterations in
      immune defenses have been suggested to be involved in liver cirrhosis and its complications.
      Dysfunction in the intestinal barrier for example results in the ongoing passage of toxic
      substances from the gastrointestinal tract that may damage the liver, leading to oxidative
      stress, inflammation and eventually liver cirrhosis. In addition, bacterial translocation is
      considered a key step in the development of spontaneous infections, mainly SBP, in patients
      with liver cirrhosis.

      The investigators hypothesize that patients with decompensated liver cirrhosis have a more
      impaired intestinal epithelial barrier and altered intestinal microbiota than patients with
      compensated liver cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary aim is to study differences in small and large intestinal permeability between patients with compensated and decompensated cirrhosis by means of a sugar permeability test</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess tight junction structure and proteins in biopsy specimens of small and large intestine</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Compensated liver cirrhosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Decompensated liver cirrhosis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be selected from a hospital providing both secondary and tertiary
        care
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis of any cause

          -  A score of greater-than or equal to 5 assessed according to the Child-Pugh
             classification

          -  Age between 18 and 65 years

        Exclusion Criteria:

          -  Known gastrointestinal diseases (such as inflammatory bowel disease and celiac
             disease), chronic renal disease (i.e. a glomerular filtration rate of less-than or
             equal to 60 ml/min per 173 m2 estimated from the Modification of Diet in Renal Disease
             (MDRD) equation) or Diabetes Mellitus

          -  Major abdominal surgery interfering with gastrointestinal function (except for
             uncomplicated appendectomy, cholecystectomy and hysterectomy, other surgery upon
             judgement of the principle investigator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A Masclee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsten Pijls, MD</last_name>
    <phone>+31433882157</phone>
    <email>k.pijls@intmed.unimaas.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Pijls, MD</last_name>
      <phone>0031433882157</phone>
      <email>k.pijls@maastrichtuniversity.nl</email>
    </contact>
    <investigator>
      <last_name>Ad Masclee, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kirsten Pijls, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>December 15, 2010</last_update_submitted>
  <last_update_submitted_qc>December 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. dr. A. Masclee</name_title>
    <organization>Maastricht University Medical Center, Division of Gastroenterology-Hepatology</organization>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>intestinal permeability</keyword>
  <keyword>microbiota</keyword>
  <keyword>complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

